Zilucoplan 自我皮下注射治疗中重度全身型肌无力的 2 期随机对照试验
这项 2 期随机双盲安慰剂对照试验纳入 44 例乙酰胆碱受体抗体阳性中重度全身型肌无力患者,评估每日皮下注射 zilucoplan 的疗效与安全性。Zilucoplan 安全性和耐受性良好。
要点
- 0.3 mg/kg 每日皮下注射 zilucoplan 第 12 周 QMG 和 MG-ADL 均较安慰剂显著改善。
- 0.1 mg/kg 剂量亦达统计学显著,但起效更慢且改善幅度较小。
- 0.3 mg/kg 组无需补救治疗,安慰剂组 15 例中 3 例需补救治疗。
核心结论
- Zilucoplan 在中重度 AChR-Ab 阳性 gMG 患者中 12 周内产生快速、有意义且持续的改善。
- 接近完全补体抑制可能优于次最大抑制。
- Zilucoplan 安全性和耐受性良好。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心 2 期临床试验,在北美 25 个中心开展。
- 患者按 1:1:1 随机接受每日皮下自我注射安慰剂、0.1 mg/kg 或 0.3 mg/kg zilucoplan,持续 12 周。
- 主要终点为 QMG 评分从基线至第 12 周的变化,关键次要终点为 MG-ADL 评分变化。
主要发现
- MG Composite 和 MG 生活质量评分等次要终点亦见临床有意义且统计学显著的改善。
- 0.1 mg/kg 组结果亦达统计学显著,但起效更慢且改善幅度不及 0.3 mg/kg 组。
- 补救治疗(静脉注射免疫球蛋白或血浆置换)在安慰剂组 15 例中 3 例、0.1 mg/kg 组 15 例中 1 例、0.3 mg/kg 组 14 例中 0 例。
关键数值与推荐
- 纳入标准为 AChR-Ab 阳性 gMG 且基线 QMG 评分至少 12 分,不限既往治疗史。
临床怎么用
- 对于中重度 AChR-Ab 阳性 gMG 患者,每日皮下自我注射 zilucoplan 0.3 mg/kg 可在 12 周内改善肌无力症状和日常生活活动能力。
- 0.3 mg/kg 剂量在起效速度和改善幅度上优于 0.1 mg/kg,且补救治疗需求更低。
- Zilucoplan 安全性良好,可作为需要靶向治疗且耐受性良好的患者的候选方案。
局限性
- 样本量较小(44 例),研究为 2 期试验。
- 研究人群以白人为主,平均年龄 45.5 至 54.6 岁。
- 随访时间仅 12 周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Many patients with generalized myasthenia gravis (gMG) have substantial clinical disability, persistent disease burden, and adverse effects attributable to chronic immunosuppression. Therefore, there is a significant need for targeted, well-tolerated therapies with the potential to improve disease control and enhance quality of life. OBJECTIVE: To evaluate the clinical effects of zilucoplan, a subcutaneously (SC) self-administered macrocyclic peptide inhibitor of complement component 5, in a broad population of patients with moderate to severe gMG. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled phase 2 clinical trial at 25 study sites across North America recruited participants between December 2017 and August 2018. Fifty-seven patients were screened, of whom 12 did not meet inclusion criteria and 1 was lost to follow-up after randomization but before receiving study drug, resulting in a total of 44 acetylcholine receptor autoantibody (AChR-Ab)-positive patients with gMG with baseline Quantitative Myasthenia Gravis (QMG) scores of at least 12, regardless of treatment history. INTERVENTIONS: Patients were randomized 1:1:1 to a daily SC self-injection of placebo, 0.1-mg/kg zilucoplan, or 0.3-mg/kg zilucoplan for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary and key secondary end points were the change from baseline to week 12 in QMG and MG Activities of Daily Living scores, respectively. Significance testing was prespecified at a 1-sided α of .10. Safety and tolerability were also assessed. RESULTS: The study of 44 patients was well balanced across the 3 treatment arms with respect to key demographic and disease-specific variables. The mean age of patients across all 3 treatment groups ranged from 45.5 to 54.6 years and most patients were white (average proportions across 3 treatment groups: 78.6%-86.7%). Clinically meaningful and statistically significant improvements in primary and key secondary efficacy end points were observed. Zilucoplan at a dose of 0.3 mg/kg SC daily resulted in a mean reduction from baseline of 6.0 points in the QMG score (placebo-corrected change, -2.8; P = .05) and 3.4 points in the MG Activities of Daily Living score (placebo-corrected change, -2.3; P = .04). Clinically meaningful and statistically significant improvements were also observed in other secondary end points, the MG Composite and MG Quality-of-Life scores. Outcomes for the 0.1-mg/kg SC daily dose were also statistically significant but slower in onset and less pronounced than with the 0.3-mg/kg dose. Rescue therapy (intravenous immunoglobulin or plasma exchange) was required in 3 of 15, 1 of 15, and 0 of 14 participants in the placebo, 0.1-mg/kg zilucoplan, and 0.3-mg/kg zilucoplan arms, respectively. Zilucoplan was observed to have a favorable safety and tolerability profile. CONCLUSIONS AND RELEVANCE: Zilucoplan yielded rapid, meaningful, and sustained improvements over 12 weeks in a broad population of patients with moderate to severe AChR-Ab-positive gMG. Near-complete complement inhibition appeared superior to submaximal inhibition. The observed safety and tolerability profile of zilucoplan was favorable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03315130.
引用
- Howard JF, Nowak RJ, Wolfe GI, et al. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020. PMID: 32065623. doi:10.1001/jamaneurol.2019.5125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。